Author contributions
A.C. and J.M.
CYTOTOXICITY
S.P.F., K.J., T.H., Z.P., E.S., C.L.W., W.L., A.V.R., S.J.M. and A.R. wrote the first draft of the manuscript. A.V.R., R.F., A.S. and T.S.-S. designed, initiated and ran the clinical study protocol. A.V.R., A.S., D.A.B., D.Y.O., B.C., M.A., Y.Y., A.J.S., J.A.S. and S.M.L. enrolled, treated and cared for patients on the clinical study protocol. Z.P., E.S., Y.M., K.M.C. and C.S. performed and interpreted bioinformatics analysis. M.T.B., O.D., K.H. and M.C.Y. developed or conducted work related to peptide–HLA protein synthesis. C.L.W., S.P., M.T.B., D. An., B.Y. and B.B.Q. created the process, acquired and/or analysed data for neoTCR T cell isolation. K.J., W.L. and R.M. developed the method or performed and analysed the studies for non-viral precision TCR replacement. A.J.L. developed and conducted the functional cytotoxicity experiments. B.S., A.C. and J.M. developed the methods, performed studies and analysed or interpreted data for product selection. Cell and plasmid manufacturing processes were created and supervised by I.M., D. Anaya. and L.D. Flow cytometry was performed, analysed or supervised by S.P.F., T.H., S.G., E.Y.-H.H., A.H., M.K., W.W., L.S., E.H., V.M. and B.P. (for the final cell product) and S.P.F., T.H., S.G., E.H. and A.H. (after infusion). T.H. analysed serum cytokines. A.H.C.N. and Y.L. performed fluorescence microscopy and together with J.R.H. scored and interpreted the staining results. S.P., M.T.B., A.F., S.J.M., D.B., J.R.H. and A.R. conceived the initial idea and provided scientific input for neoTCR cell isolation for personalized adoptive cell therapy. All authors proofread and approved the final manuscript.